delays to market access in europe november 2002 1 contents introduction 3 2 definitions of terms used 5 methodology 7 4 analysis time taken for pricing and or reimbursement approval 9 overall each specific hospital only ambulatory care products 12 countries with separate procedures a combined procedure publication 14 6 country issues be considered analysing restrictions on usage 16 conclusions 17 annex medicinal included this study 19 innovative medicines are not available all european citizens at the same some markets patients may have wait more than two years before being able new medicine from industry s patient perspective it is imperative ensure that come timely fashion accordance timelines established by relevant directive an adequate price
